Ethics Over Efficacy: The Remdesivir Dilemma

In 2018, remdesivir was deemed too lethal for use in Ebola trials by the World Health Organization, with a staggering 53% fatality rate among those treated, surpassing the death rate of Ebola itself. This raised serious ethical concerns, leading to the drug's removal from clinical trials due to its high mortality risk. The situation highlights significant moral implications regarding the use of potentially fatal drugs in vulnerable populations, questioning the integrity of health organizations when safety standards are breached.